Pharm-Olam stands with the global community and the fight against COVID-19. No other disease in recent history has captured the world like Coronavirus. As an Infectious Disease CRO and Vaccine CRO, we are poised to help pharmaceutical and biotechs by rapidly deploying their clinical trials in the search for vaccines and therapies to fight this infectious disease. Together, we can create a healthier world.
We have several on-going COVID-19 studies and are proud to have been selected by the US Department of Defense as a CRO prime contractor in support of Operation Warp Speed.
We understand that drug development partners with medical countermeasures (MCM) expertise are crucial in bringing vaccines and treatments to the front lines of the COVID-19 battle. As an MCM-capable CRO, Pharm-Olam is ready to go the distance in supporting those studies.
We can help! Pharm-Olam currently holds memberships in the Medical CBRN Defense Consortium (MCDC). We also work with the DoD's Other Transaction Authority (OTA) and under Other Transactions (OTs).
We have supported federally-funded research for more than 20 years. We can support your organization's effort to secure government funding. Our proven track record has allowed us to collaborate on over $778M in government-funded trials with several agencies including the NIH, DOD, BARDA, and CDC.
Learn More
As an infectious disease CRO and vaccine CRO, we often have to bring our clinical research efforts to the patients where they are. Our Expeditionary capabilities allow us to add over 30 additional countries to our global coverage. We leverage our staff with strategically-advantageous site relationships and partner networks to reach patients in remote regions.
Learn More
Today it's the coronavirus COVID-19. Tomorrow, it will be something else. Pharm-Olam maintains staff with deep expertise in infectious diseases and vaccines. Roughly 84% of PMs and 79% of CRAs have ID&V expertise. We are ready to go the distance to support finding new vaccines and therapeutics.
As an Infectious Disease CRO, we have deep roots in supporting anti-infective development. Our long and successful history in the anti-infective area of drug development is demonstrated by supporting more than 50% of all NCE antibiotics approved by FDA since 2013.
Sponsor Testimonial
Biotech - Director ClinOps